MAPT and Alzheimer disease: These participants were categorized as having significant AD pathologic change (n = 59) or not (n = 46) based on the Alzheimer's disease neuropathologic change (ADNC) scale, in which both amyloid and tau pathologies are accounted for (Montine et al, 2012).